Q2 2026 saw 15.2% worldwide revenue growth, record physician engagement, and a 178% improvement in adjusted EBITDA. Updated FY26 guidance projects $231–$233 million in revenue and sustained 79% gross margin, with robust liquidity and strong U.S. market momentum.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.